ETFs positioned on Zealand Pharma A/S

Name YTD change Weight AuM
0.00%-0% 12 M€
Logo Zealand Pharma A/S
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2025, the Group had a portfolio of 8 products in clinical development (including 3 in phase III, 3 in phase II and 2 in phase I), and 1 product in preclinical development.
Employees
544
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
252.30DKK
Average target price
525.73DKK
Spread / Average Target
+108.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ZEAL Stock
  4. ETFs Zealand Pharma A/S
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW